BACKGROUND: Survival of HIV-infected children continues to increase and the use of antiretrovirals (ARVs) is expanding; however there are few data regarding the incidence of renal dysfunction and associated risk factors among HIV-infected children and youth. METHODS: A total of 2102 children enrolled in Pediatric AIDS Clinical Trials Group Study 219/219C, were followed and assessed prospectively for >30 months. Occurrence of clinical events and laboratory abnormalities were recorded using standardized criteria and forms. Therapeutic decisions were made by clinicians at each site. Occurrence of persistent renal laboratory abnormalities was the main outcome measure. RESULTS: Four hundred forty-six (22%) enrollees exhibited at least one persistent renal laboratory abnormality. Elevated serum creatinine (Cr) was more common than persistent proteinuria (15% vs. 8%). The incidence of new renal laboratory abnormalities was 3.7 events per 100 person-years with rates increasing between 1993 and 2005. Older age (>or=6 years vs. <6 years), Hispanic ethnicity, and Black non-Hispanic race were associated with increased risk of renal dysfunction, but CDC clinical class and plasma HIV RNA levels were not. Subjects exposed to ARV regimens containing tenofovir and/or indinavir had approximately twice the risk of developing renal dysfunction compared with persons exposed to other ARVs. The risk of renal dysfunction was also elevated for other antivirals (hazard ratio = 5.4) and amphotericin B (hazard ratio = 28). CONCLUSIONS: Persistent renal function abnormalities occur frequently in HIV-infected children. Improved survival, Black race and Hispanic ethnicity, and exposure to tenofovir, indinavir, and other antimicrobial agents increase the risk for renal dysfunction. All HIV-infected children should be monitored closely for evidence of renal disease.
BACKGROUND: Survival of HIV-infectedchildren continues to increase and the use of antiretrovirals (ARVs) is expanding; however there are few data regarding the incidence of renal dysfunction and associated risk factors among HIV-infectedchildren and youth. METHODS: A total of 2102 children enrolled in Pediatric AIDS Clinical Trials Group Study 219/219C, were followed and assessed prospectively for >30 months. Occurrence of clinical events and laboratory abnormalities were recorded using standardized criteria and forms. Therapeutic decisions were made by clinicians at each site. Occurrence of persistent renal laboratory abnormalities was the main outcome measure. RESULTS: Four hundred forty-six (22%) enrollees exhibited at least one persistent renal laboratory abnormality. Elevated serum creatinine (Cr) was more common than persistent proteinuria (15% vs. 8%). The incidence of new renal laboratory abnormalities was 3.7 events per 100 person-years with rates increasing between 1993 and 2005. Older age (>or=6 years vs. <6 years), Hispanic ethnicity, and Black non-Hispanic race were associated with increased risk of renal dysfunction, but CDC clinical class and plasma HIV RNA levels were not. Subjects exposed to ARV regimens containing tenofovir and/or indinavir had approximately twice the risk of developing renal dysfunction compared with persons exposed to other ARVs. The risk of renal dysfunction was also elevated for other antivirals (hazard ratio = 5.4) and amphotericin B (hazard ratio = 28). CONCLUSIONS: Persistent renal function abnormalities occur frequently in HIV-infectedchildren. Improved survival, Black race and Hispanic ethnicity, and exposure to tenofovir, indinavir, and other antimicrobial agents increase the risk for renal dysfunction. All HIV-infectedchildren should be monitored closely for evidence of renal disease.
Authors: Robert C Kalayjian; Nora Franceschini; Samir K Gupta; Lynda A Szczech; Ezekiel Mupere; Ronald J Bosch; Marlene Smurzynski; Jeffrey M Albert Journal: AIDS Date: 2008-02-19 Impact factor: 4.177
Authors: Murli U Purswani; Miriam C Chernoff; Charles D Mitchell; George R Seage; Gaston Zilleruelo; Carolyn Abitbol; Warren A Andiman; Kathleen A Kaiser; Hans Spiegel; James M Oleske Journal: Pediatr Nephrol Date: 2012-02-26 Impact factor: 3.714
Authors: Charles D Mitchell; Miriam C Chernoff; George R Seage; Murli U Purswani; Hans M L Spiegel; Gaston Zilleruelo; Carolyn Abitbol; Barbara Heckman; Christopher B Ponce; James M Oleske Journal: Pediatr Nephrol Date: 2014-08-24 Impact factor: 3.714
Authors: Cristina B Hofer; D Robert Harris; Ricardo Hugo de Oliveira; Thalita F de Abreu; Fabiana Kakehasi; Jose Henrique Pilotto; Noris Pavia Ruz; Margot R Krauss; Rohan Hazra Journal: AIDS Res Hum Retroviruses Date: 2014-07-16 Impact factor: 2.205
Authors: Aylin B Unsal; Aviva S Mattingly; Sara E Jones; Julia B Purdy; James C Reynolds; Jeffrey B Kopp; Rohan Hazra; Colleen M Hadigan Journal: J Clin Endocrinol Metab Date: 2017-08-01 Impact factor: 5.958
Authors: Gregory M Lucas; Michael J Ross; Peter G Stock; Michael G Shlipak; Christina M Wyatt; Samir K Gupta; Mohamed G Atta; Kara K Wools-Kaloustian; Paul A Pham; Leslie A Bruggeman; Jeffrey L Lennox; Patricio E Ray; Robert C Kalayjian Journal: Clin Infect Dis Date: 2014-09-17 Impact factor: 9.079
Authors: Denise L Jacobson; Wendy Yu; Rohan Hazra; Sean Brummel; Mitchell E Geffner; Kunjal Patel; William Borkowsky; Jiajia Wang; Janet S Chen; Ayesha Mirza; Linda A DiMeglio Journal: Bone Date: 2020-06-30 Impact factor: 4.398
Authors: Murli Purswani; Kunjal Patel; Jeffrey B Kopp; George R Seage; Miriam C Chernoff; Rohan Hazra; George K Siberry; Lynne M Mofenson; Gwendolyn B Scott; Russell B Van Dyke Journal: Pediatr Infect Dis J Date: 2013-05 Impact factor: 2.129